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Background
• Worldwide infection rates for HPV are
estimated to range from 9% to 13%, equaling
20 million women affected in the US alone [1].
• Human papillomavirus (HPV) cancers are
uniquely antigenic with ubiquitous and
essential expression of viral proteins E6 and
E7 [2].
• It has been shown that anti-tumor T cells
responses after adoptive T cell therapy in
HPV-positive tumors target non-viral antigens
rather than viral antigens, suggesting
vaccines alone may be insufficient to treat
cervical cancer [3].
• TCRs can be used as a biomarker to identify
underlying immunity to specific antigens [4].
We have identified 1,331 TCRs which are
increased in tumor specimens incubated the
HPV antigens.
• We hypothesize that the radiation therapy
may synergize with vaccine treatments to
stimulate T-cell mediated anti-tumor.

Objective
• We are investigating the effect of PDS0101,
an E6/7 HPV16 T-cell activating
immunotherapy delivered subcutaneously,
combined with the standard of care
chemoradiation for patients with locally
advanced squamous cell cervical cancer.
• Characterize antigen- specific
populations.
• Identify HPV responsive T-cells using
TCR sequencing.
• Determine if previously identified
population of HPV-reactive T-cells
correlate with treatment outcome in
patients treated with vaccine and
chemoradiation.
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Figure 1. Schema for IMMUNOCERV trial delivering PDS0101 with
standard CRT.
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• Cervical Swabs are collected at each timepoint (T)
shown in Figure 1.
• Genomic DNA from Cervical Swab was isolated using
Isohelix™ Xtreme DNA Isolation Kit.
• Isolated genomic DNA was amplified in a biascontrolled multiplex PCR.
• The CDR3 regions of human TCR-β chains were
sequenced using immunoSEQ assay (Adaptive
Biotechnologies, Seattle, WA).
• Analyses were performed to assess the diversity of
TCR in each timepoint (T0, T1, T2, T3, 4, T4B, T5).
• Detected T cells clones with TCR-β sequences
expected to generate functional TCRs (productive
rearrangements).
• Evaluated differential abundance at T4 and T4B by
using IMMUNOSEQ analyzer.
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Methods
• This project is a part of the IMMUNOCERV
trial. The criteria of inclusion of this trial are
patients with locally advanced squamous cell
cervical cancer with either lymph node
metastasis or tumors of >5 cm.
• Subjects
• 8 patients to date have completed
treatment and have been evaluated with
post-treatment PET (Positron Emission
Tomography) scan to evaluate response.
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Figure 2. HPV type
impacts TCR expansion.
(A) (B) TCRs expanded
from T4 to T4B in PDS03
and PDS05. (C) TCRs did
not expand from T4 to
T4B in PDS06. The
differences were HPV
type; HPV16 (PDS03 and
PDS05) and HPV18
(PDS06).
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Figure 3. Key TCRs were identified in PDS03, PDS05, and
PDS06. (A) PDS03 had 15 elevated TCRs at T4B. (B)
PDS05 had 2 elevated TCRs at T4B. (C) PDS06 had 31
elevated TCRs at T4B

Conclusion
• In this study, we:
1. Analyzed the diversity of TCRs over the
course of the treatment.
2. Identified TCR clones that increased at
the end of treatment.
• HPV16 positive patients had expanded TCR
clones from T4 to T4B.
• Our results suggests that brachytherapy
synergizes with the vaccine to increase HPV
responsive clones, specifically these TCR
clones.
• Further analysis will be needed to determine
the role and function of these identified HPVreactive TCRs in cervical cancer immune
responses and combination therapy.
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